

## List of Contents

<b>1</b>	<b>Potential Agents of Bioterrorism: Historical Perspective and an Overview</b>	<b>1</b>
	<i>Nancy Khardori</i>	
1.1	Historical Perspective – How We Got Here	1
1.2	Development of Modern Biological Weapons	3
1.3	Biological Weapons Systems	8
1.4	Potential Bioterrorism Agents – Categorization and Prioritization	10
1.5	Category B – Bacterial/Rickettsial Agents of Bioterrorism	14
1.5.1	Brucellosis	14
1.5.2	Glanders and Melioidosis	15
1.5.3	Psittacosis	17
1.5.4	Q Fever	18
1.5.5	Typhus Fever	19
1.5.6	Food and Water Safety Threats	21
1.6	Category B – Viral Agents of Bioterrorism	22
1.6.1	Alphavirus Encephalomyelitis	22
1.7	Category B – Biological Toxins for Bioterrorism	23
1.7.1	Enterotoxin B	23
1.7.2	Epsilon (Alpha Toxin)	24
1.7.3	Ricin Toxin	24
1.7.4	T-2 Mycotoxins	24
1.8	Other Toxins With Potential for Bioterrorism	25
1.8.1	Nipah and Hendra Viruses	26
1.9	Emerging Threats and Potential Agents of Bioterrorism	26
1.9.1	Pandemic Influenza – Human and Avian Influenza Viruses	26
1.9.2	Severe Acute Respiratory Syndrome (SARS) – SARS-associated Coronavirus (SARS–COV)	27
1.9.3	Other Emerging Threats	27

<b>2</b>	<b>Bioterrorism Preparedness: Historical Perspective and an Overview</b>	<b>33</b>
	<i>Nancy Khardori</i>	
2.1	Introduction	33
2.2	International Biodefense Actions in the Nineteenth Century and Their Impact	34
2.3	Civilian Biodefense – The Obstacles	36
2.4	Bioterrorism Preparedness – The Rationale	39
2.5	Bioterrorism Preparedness – The Avenues	40
2.5.1	Public Health Laws	40
2.5.2	Public Health System Preparedness	42
2.5.3	Political Preparedness	52
2.5.4	Bioterrorism Preparedness – Global Avenues	53
<b>3</b>	<b>Care of Children in the Event of Bioterrorism</b>	<b>73</b>
	<i>Subhash Chaudhary</i>	
3.1	Introduction	73
3.2	Increased Vulnerability of Children	73
3.2.1	Anatomic and Physiological Features Placing Children at Increased Risk of Vulnerability	74
3.2.2	Developmental Factors Involved in Increased Vulnerability of Children	75
3.2.3	Delayed Diagnosis in Children	76
3.2.4	Unique Management Needs of Children	76
3.2.5	Decontamination Showers	76
3.2.6	Doses of Medication	76
3.2.7	Size of Equipment	76
3.2.8	Training of Healthcare Workers to Meet the Special Needs of Children	77
3.2.9	Communication with Children about Disasters	77
3.2.10	Communication with Adolescents about Disasters	77
3.3	Categories of Biological Agents and Toxins	78
3.3.1	Smallpox (Variola)	78
3.3.2	Anthrax	81
3.3.3	Botulism	84
3.3.4	Plague	87
3.3.5	Tularemia	88
<b>4</b>	<b>Smallpox: Virology, Clinical Presentation, and Prevention</b>	<b>93</b>
	<i>James M. Goodrich</i>	
4.1	Introduction	93
4.2	History	94
4.3	Virology	94

4.4	Clinical Features and Classification	96
4.4.1	Rash and Prognosis	96
4.5	The Stages of Smallpox	96
4.5.1	Incubation Period	97
4.5.2	Pre-eruptive Stage	98
4.5.3	Eruptive Stage	100
4.6	Ordinary Type	100
4.6.1	Death	103
4.7	Modified-type	104
4.7.1	Variola Sine Eruptione and Subclinical Infection	104
4.8	Flat-type	104
4.9	Hemorrhagic-type	105
4.10	Early Hemorrhagic-type	106
4.11	Late Hemorrhagic-type	106
4.12	Complications	107
4.12.1	Skin	107
4.12.1	Respiratory	108
4.12.1	Gastrointestinal	108
4.12.1	Neurological	108
4.12.1	Ophthalmic	108
4.12.1	Osteo-articular	108
4.13	Differential Diagnosis	109
4.14	Pathophysiology	111
4.15	Laboratory Diagnosis	112
4.16	Postexposure Infection Control	113
4.17	Vaccination and Immunity	113
4.18	Antiviral Treatment	116
4.19	Summary	117
<b>5</b>	<b>Anthrax – Bacteriology, Clinical Presentations, and Management</b>	<b>123</b>
	<i>Nancy Khardori</i>	
5.1	Historical Background	123
5.2	Epidemiology	124
5.3	Microbiology and Genetics	125
5.4	Virulence Factors and Pathogenesis	127
5.5	Human Anthrax – Clinical Manifestations	128
5.5.1	Cutaneous Anthrax	128
5.5.2	Gastrointestinal Anthrax	129
5.5.3	Inhalational Anthrax	130
5.5.4	Hemorrhagic Meningoencephalitis	132
5.5.5	Microbiological Diagnosis	132
5.5.6	Immunological Tests and Serological Diagnosis	134

- 5.5.7 Antimicrobial Therapy and Post-exposure Prophylaxis 135
- 5.5.8 Emerging/Investigational Therapies 136
- 5.5.9 Human Vaccination 137
- 5.5.10 Anthrax Vaccines in Development 138
- 5.5.11 Infection Control and Decontamination 139

**6 Plague: Endemic, Epidemic, and Bioterrorism 147**

*Janak Koirala*

- 6.1 Introduction 147
- 6.2 History 147
- 6.3 Microbiology 148
- 6.4 Global Epidemiology 148
- 6.5 Pathogenesis 149
- 6.6 Clinical Features 150
  - 6.6.1 Bubonic Plague 151
  - 6.6.2 Primary Septicemic Plague 151
  - 6.6.3 Primary Pneumonic Plague 151
  - 6.6.4 Other Forms 152
- 6.7 Mortality 152
- 6.8 Laboratory Diagnosis 152
- 6.9 Radiology 154
- 6.10 Potential as a Biological Weapon 154
- 6.11 Features of Bioterrorism 154
- 6.12 Diagnosis 155
- 6.13 Treatment 156
- 6.14 Prevention 158
  - 6.14.1 Immunization 159
  - 6.14.2 Antibiotic Prophylaxis 159
  - 6.14.3 Infection Control 160

**7 Botulism: Toxicology, Clinical Presentations and Management 163**

*Janak Koirala*

- 7.1 Introduction 163
- 7.2 History 163
- 7.3 Epidemiology 164
- 7.4 Microbiology and Toxicology 165
- 7.5 Transmission 168
- 7.6 Clinical Features 168
- 7.7 Diagnosis 169
- 7.8 Differential Diagnosis 171
- 7.9 Potential as a Biological Weapon 172
- 7.10 Features of a Botulism Attack 173
- 7.11 Management 174
- 7.12 Prognosis 174

7.13	Prevention	175
7.13.1	Immunization	175
7.13.2	Post-exposure Prophylaxis	176
7.13.3	Decontamination	176
7.14	Infection Control	176
<b>8</b>	<b>Tularemia: Natural Disease or Act of Terrorism</b>	<b>181</b>
	<i>Janak Koirala</i>	
8.1	Introduction	181
8.2	History	181
8.3	Microbiology	182
8.4	Epidemiology	183
8.5	Pathogenesis	184
8.6	Clinical Features	184
8.7	Laboratory Diagnosis	186
8.8	Radiology	187
8.9	Potential as Biological Weapon	187
8.10	Diagnostic Criteria	188
8.11	Treatment	189
8.12	Prevention	191
8.12.1	Immunization	191
8.12.2	Post-exposure Prophylaxis	191
8.13	Infection Control	191
8.14	Reporting to the Public Health System	192
<b>9</b>	<b>Viral Hemorrhagic Fevers: Differentiation of Natural Disease from Act of Bioterrorism</b>	<b>195</b>
	<i>James M. Goodrich</i>	
9.1	Introduction	195
9.2	Filoviridae	199
9.2.1	Virology	199
9.2.2	Epidemiology	199
9.2.3	Clinical Manifestations and Disease	200
9.2.4	Transmission	202
9.2.5	Pathogenesis	203
9.2.6	Diagnosis	204
9.3	Arenaviridae	205
9.3.1	Virology	205
9.3.2	Epidemiology	206
9.3.3	Clinical Manifestations and Disease	206
9.3.4	Transmission	208
9.3.5	Diagnosis	208

9.4	Bunyaviridae	208
9.4.1	Virology	208
9.4.2	Epidemiology	209
9.4.3	Clinical Manifestations and Disease	209
9.4.4	Transmission	211
9.4.5	Diagnosis	211
9.5	Flaviviridae and Other Viruses	212
9.5.1	Kyasanur Forest Disease	212
9.5.2	Omsk Hemorrhagic Fever Virus	212
9.6	Alphaviruses	213
<b>10</b>	<b>Policy Priorities: Smallpox, Stockpiles, and Surveillance</b>	<b>225</b>
	<i>Ross D. Silverman</i>	
10.1	Introduction	225
10.2	Smallpox Preparedness and Pre-event Vaccination	225
<b>11</b>	<b>Legal Preparedness: The Modernization of State, National, and International Public Health Law</b>	<b>239</b>
	<i>Ross D. Silverman</i>	
11.1	Legal Preparedness: Sources of Power and Limits	239
11.2	Federal Public-health Authority	241
11.3	Federal Isolation and Quarantine Powers	243
11.4	International Health Regulations	244
11.5	Legal Preparedness	246
11.6	Legal Preparedness in Action: The Model State Emergency Health Powers Act	247
	<b>Index</b>	<b>253</b>